Cancer Genetics, Inc., an early-stage diagnostics company, focuses on the development and commercialization of proprietary genomic tests and services to improve and personalize the diagnosis, prognosis, and response to treatment of cancer. The company offers a range of services in various areas, including microarray based testing, a proprietary microarray test for the detection of chromosomal abnormalities observed in Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma and Diffuse Large B-cell Lymphoma; molecular testing to analyze DNA and RNA to follow progression of disease and response to therapy at the genetic level; cytogenetics testing, a series of methods for analyzing human chromosomes to identify malignancy; fish testing, an analysis of abnormalities at the chromosomal and gene levels; flow cytometry testing, an immuno pheno - type analysis of specific markers inside cells; histology testing, a microscopic examination of stained tissue sections; cytology testing, a non-gynecological fluid preparation for microscopic evaluations by a pathologist; and IHC testing, an analysis of the distribution of tumor antigens in specific cell and tissue types. It offers DNA-based cancer diagnostics and services medical institutions. The company's tests target cancers, including hematological, urogenital, and HPV-associated cancers. It also provides a range of non-proprietary oncology-focused tests and laboratory services that offer critical genomic information to healthcare professionals, as well as biopharma and biotech. The company was founded in 1999 and is headquartered in Rutherford, New Jersey.